Get the Stockscreener App
11.46
4.18%
-0.50
After Hours:
11.59
0.13
+1.13%
Omeros Corp stock is traded at $11.46, with a volume of 1.52M.
It is down -4.18% in the last 24 hours and down -14.29% over the past month.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
See More
Previous Close:
$11.96
Open:
$11.84
24h Volume:
1.52M
Relative Volume:
1.32
Market Cap:
$829.42M
Revenue:
-
Net Income/Loss:
$-4.81M
P/E Ratio:
-22.93
EPS:
-0.4998
Net Cash Flow:
$-122.54M
1W Performance:
-6.45%
1M Performance:
-14.29%
6M Performance:
+29.20%
1Y Performance:
+255.90%
1-Day Range:
$11.46
$11.97
1-Week Range:
$11.41
$12.55
52-Week Range:
$2.95
$17.65
Omeros Corp Stock (OMER) Company Profile
Name
Omeros Corp
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
11.46 | 865.61M | 0 | -4.81M | -122.54M | -0.4998 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corp Stock (OMER) Latest News
Why did Omeros stock jump 5% in after-hours trading today? - MSN
[144] OMEROS CORP SEC Filing - Stock Titan
OMER Technical Analysis & Stock Price Forecast - Intellectia AI
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA - MSN
Earnings call transcript: Omeros Q1 2026: Stock dips after earnings miss - Investing.com
OMER Stock Price, Quote & Chart | OMEROS CORP (NASDAQ:OMER) - ChartMill
Seattle InnoSEngine headed to Bothell I An update on Omeros - The Business Journals
Omeros Corporation (NASDAQ:OMER) Q1 2026 Earnings Call Transcript - Insider Monkey
Omeros (OMER) Q1 2026 Earnings Transcript - The Globe and Mail
OMER Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Omeros Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Omeros (OMER) Reports Strong Q1 2026 Earnings and Positive Cash Flow from YARTEMLEA - GuruFocus
Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YART - GuruFocus
OMER SWOT Analysis: Key Insights from Q1 2026 10-Q Filing - GuruFocus
Omeros Q1 Earnings Call Highlights - Barchart
How Should Investors Value Omeros (OMER) After Q1 2026 EPS $0.62 - GuruFocus
Omeros (OMER) Reports Q1 Revenue and Highlights Growth Initiativ - GuruFocus
Omeros Q1 2026 Earnings Call Transcript - MarketBeat
Omeros earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Omeros misses Q1 2026 expectations, stock dips - Investing.com
Omeros Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts - ChartMill
OMEROS ($OMER) Releases Q1 2026 Earnings - Quiver Quantitative
Q1 2026 Omeros Corp Earnings Call Transcript - GuruFocus
Omeros: Q1 Earnings Snapshot - Barchart.com
YARTEMLEA launch and zaltenibart deal reshape Omeros (NASDAQ: OMER) - Stock Titan
Omeros (NASDAQ: OMER) turns Q1 profit on YARTEMLEA sales and CMS gains - Stock Titan
New transplant drug gains Medicare billing code, logs $11M sales - Stock Titan
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 - BioSpace
TradingKey - TradingKey
Omeros earnings up next as investors eye YARTEMLEA launch By Investing.com - Investing.com South Africa
100% Of This Omeros Insider's Holdings Were Sold - Moomoo
OMER stock on track for best week in nearly 4 months after receiving permanent reimbursement code for treatment - MSN
UBS Group AG Grows Position in Omeros Corporation $OMER - MarketBeat
MSN Money - MSN
Assessing Omeros (OMER) Valuation After Recent Share Price Rebound And Novo Nordisk Deal Prospects - simplywall.st
Omeros Corporation (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Omeros (NASDAQ:OMER) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
OMEROS CORP ($OMER) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay, incentives and votes detailed in Omeros (NASDAQ: OMER) 2026 proxy - Stock Titan
[ARS] OMEROS CORP SEC Filing - Stock Titan
Omeros rises as Novo deal boosts Q4 earnings - MSN
OMER stock surges 5% after hours on Novo Nordisk deal windfall and drug launch optimism - MSN
Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and Brainsway - Yahoo Finance
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside - MSN
Omeros (NASDAQ:OMER) Trading 6.3% HigherShould You Buy? - MarketBeat
Here's Why Omeros (OMER) is a Great Momentum Stock to Buy - Yahoo Finance
Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade - Yahoo Finance
Omeros Corp Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):